Related Experiment Video
Updated: May 26, 2026
Hemodynamic Precision in the Neonatal Intensive Care Unit using Targeted Neonatal Echocardiography
Published on: January 27, 2023
Should we definitively abandon prophylaxis for patent ductus arteriosus in preterm new-borns?
Vassilios Fanos1, Michele Pusceddu, Angelica Dessì
1Neonatal Intensive Care Unit, Puericulture Institute And Neonatal Section, AOU University of Cagliari, Italy.
Insights
Prophylactic indomethacin in extremely low-birth weight infants does not improve long-term outcomes. Routine use is not recommended due to side effects, but individualized prophylaxis may be possible.
Area of Science:
- Neonatal medicine
- Pharmacology
- Developmental neuroscience
Background:
- Patent ductus arteriosus and intraventricular hemorrhage are common in extremely low-birth weight infants.
- Indomethacin prophylaxis is used to prevent these conditions.
Purpose of the Study:
- To evaluate the long-term benefits of prophylactic indomethacin in extremely low-birth weight infants.
- To assess the risks associated with indomethacin, including effects on blood flow and organ systems.
Main Methods:
- Review of existing literature on indomethacin prophylaxis in preterm neonates.
- Analysis of outcomes including survival, neurosensory, and cognitive development.
- Consideration of physiological effects of indomethacin on renal, intestinal, and cerebral blood flow.
Main Results:
- Indomethacin reduces the incidence of patent ductus arteriosus and severe intraventricular hemorrhage.
- No significant long-term benefits in survival or neurodevelopmental outcomes were observed.
- Indomethacin causes a reduction in renal, intestinal, and cerebral blood flow.
Conclusions:
- Routine prophylactic indomethacin is not recommended for preterm neonates due to lack of long-term benefit and potential adverse effects.
- Individualized prophylaxis strategies, potentially incorporating genetic background and metabolomics, may be a future direction for NSAID use.
Abstract:
Although the prophylactic administration of indomethacin in extremely low-birth weight infants reduces the frequency of patent ductus arteriosus and severe intraventricular hemorrhage, it does not appear to provide any long-term benefit in terms of survival without neurosensory and cognitive outcomes. Considering the increased drug-induced reduction in renal, intestinal, and cerebral blood flow, the use of prophylaxis cannot be routinely recommended in preterm neonates. However, a better understanding of the genetic background of each infant may allow for individualized prophylaxis using NSAIDs and metabolomics.
